Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors Academic Article uri icon

Overview

MeSH Major

  • Aromatase Inhibitors
  • Leiomyosarcoma
  • Uterine Neoplasms

abstract

  • In this population of patients with mostly low-volume and ER positive uterine LMS, aromatase inhibitors achieved objective response in only 9%. Relatively prolonged PFS was observed among ER positive uterine LMS patients. In the absence of a no-treatment control group, the prolonged PFS cannot be attributed solely to the activity of the aromatase inhibitor treatment since it may reflect the underlying biology of low-volume, ER positive uterine LMS.

publication date

  • March 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4852374

Digital Object Identifier (DOI)

  • 10.1016/j.ygyno.2009.10.064

PubMed ID

  • 19932916

Additional Document Info

start page

  • 424

end page

  • 9

volume

  • 116

number

  • 3